AstraZeneca Covid-19 vaccine trial volunteer dies, did not receive dose

Oxford confirmed the plan to keep testing

Vaccine
Anvisa provided no further details, citing medical confidentiality of those involved in trials
Reuters
2 min read Last Updated : Oct 22 2020 | 1:26 PM IST
Brazilian health authority Anvisa said on Wednesday that a volunteer in a clinical trial of the Covid-19 vaccine developed by AstraZeneca and Oxford University had died but added that the trial would continue.

Oxford confirmed the plan to keep testing, saying in a statement that after careful assessment "there have been no concerns about safety of the clinical trial." A source familiar with the matter told Reuters that the trial would have been suspended if the volunteer who died had received the Covid-19 vaccine, suggesting the person was part of the control group that was given a meningitis vaccine.

CNN Brasil reported that the volunteer was a 28-year-old man who lived in Rio de Janeiro and died from Covid-19 complications.

Anvisa provided no further details, citing medical confidentiality of those involved in trials.

AstraZeneca declined to comment immediately.

The Federal University of Sao Paulo, which is helping coordinate phase 3 clinical trials in Brazil, separately said the volunteer was Brazilian without revealing where the person lived.

It is up to an independent review board to decide whether trials will continue, a spokesman for the university said. The board is made up of experts not from AstraZeneca, nor the universities nor the Brazilian biomedical research center FioCruz that plans to produce the vaccine in Brazil.

So far 8,000 of the planned 10,000 volunteers in the trial have been recruited and given the first dose in six cities in Brazil, and many have already received the second shot, he said.

AstraZeneca shares fell 1.8 per cent.

Brazil's federal government has plans to purchase the UK vaccine and produce it at FioCruz in Rio de Janeiro, while a competing vaccine from China's Sinovac Biotech Ltd is being tested by Sao Paulo state's research center Butantan Institute.

Brazil has the second deadliest outbreak of the coronavirus, with more than 154,000 killed by Covid-19, following the United States. It has the third largest number of cases, with more than 5.2 million infected, after the United States and India.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusAstraZeneca

Next Story